TelosRX providers regularly evaluate patients whose lab work flags insulin resistance — often before any formal diabetes diagnosis. These are the questions that come up most often, answered directly from the published clinical literature.
What Is Insulin Resistance, and How Is It Different from Diabetes?
Insulin resistance is a state in which cells — primarily in muscle, liver, and fat tissue — respond less efficiently to insulin signaling. The pancreas compensates by producing more insulin, so blood glucose can remain normal for years even as the underlying dysfunction progresses.
Type 2 diabetes occurs when the pancreas can no longer keep pace with the insulin demand and blood glucose rises to diagnostic thresholds (fasting glucose ≥126 mg/dL or HbA1c ≥6.5%). Insulin resistance is the metabolic precursor to that transition, and it can be present for a decade or more before glucose levels cross the diagnostic line. Addressing it early — before beta-cell exhaustion — is the clinical rationale for screening people with risk factors before glucose becomes the primary concern.
What Are the Early Symptoms of Insulin Resistance?
Insulin resistance is frequently asymptomatic in its early stages. Lab work often reveals it before any physical symptoms appear. When symptoms do arise, they tend to be nonspecific:
- Central adiposity: Fat accumulation around the abdomen (visceral fat) both contributes to and results from insulin resistance. A waist circumference above 35 inches in women or 40 inches in men is a clinical marker.
- Fatigue after carbohydrate-heavy meals: Impaired glucose uptake can produce post-meal energy crashes and brain fog.
- Acanthosis nigricans: Darkened, thickened skin in skin folds (neck, armpits, groin) — caused by elevated insulin stimulating skin cell proliferation. When present, it is a strong visual indicator of significant hyperinsulinemia.
- Elevated triglycerides, low HDL: The dyslipidemia pattern associated with metabolic syndrome often co-occurs with insulin resistance. The NIDDK’s insulin resistance overview lists these as standard screening flags.
- Polycystic ovary syndrome (PCOS) in women: Hyperinsulinemia drives excess androgen production in the ovaries. PCOS and insulin resistance are tightly linked; most women with PCOS have some degree of insulin resistance.
None of these symptoms confirm insulin resistance on their own. Lab testing — at minimum a fasting insulin level alongside fasting glucose — is required for clinical assessment.
How Is Insulin Resistance Diagnosed?
There is no single universal diagnostic standard. The HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is the most widely used research and clinical tool. It requires two values: fasting insulin (μIU/mL) and fasting glucose (mg/dL).
HOMA-IR = (Fasting Insulin × Fasting Glucose) ÷ 405
A HOMA-IR below 1.0 is generally considered optimal. Values above 2.0 suggest emerging resistance; above 2.5–3.0 is typically treated as clinically significant. Reference ranges vary by laboratory and population, and interpretation should account for individual context. The NCBI StatPearls insulin resistance chapter provides a detailed breakdown of diagnostic thresholds.
Providers at TelosRX review fasting insulin, fasting glucose, HbA1c, and lipid panels as part of hormone and metabolic evaluations. If your recent labs show any of these in concerning ranges, include them when you complete your intake form.
What Hormones Drive Insulin Resistance?
Insulin does not operate in isolation. Several hormones directly modulate insulin sensitivity:
- Cortisol: Chronically elevated cortisol (from psychological stress, poor sleep, or HPA axis dysfunction) promotes hepatic glucose production and reduces peripheral insulin sensitivity. This is why stress management is a clinical intervention, not lifestyle advice.
- Testosterone (in men): Low testosterone is independently associated with insulin resistance and visceral fat accumulation. The relationship is bidirectional — insulin resistance suppresses LH signaling, which reduces testosterone production, worsening the metabolic picture. See the TelosRX TRT guide for the testosterone-metabolism connection.
- Estrogen (in women): Estrogen has insulin-sensitizing effects in premenopausal women. The decline at perimenopause correlates with increased visceral fat and worsening insulin sensitivity — a key reason metabolic health often deteriorates in the 40s and 50s.
- Thyroid hormones: Hypothyroidism reduces glucose uptake in peripheral tissues and slows hepatic glucose clearance. Even subclinical hypothyroidism can contribute to insulin resistance.
- Growth hormone and IGF-1: GH has insulin-antagonizing effects at high levels, but age-related GH decline is associated with worse body composition and metabolic function. The TelosRX hormone optimization protocol overview addresses how GH secretagogues fit into metabolic support.
Can Insulin Resistance Be Reversed?
Yes — insulin resistance is not a fixed state. It exists on a continuum, and multiple interventions have demonstrated measurable improvements in HOMA-IR in randomized controlled trials.
Exercise: Resistance training and aerobic exercise both improve insulin sensitivity through distinct mechanisms. Resistance training increases muscle GLUT4 expression; aerobic exercise improves mitochondrial density and reduces ectopic fat. A 2023 meta-analysis in Nutrients found that combined aerobic and resistance exercise produced greater HOMA-IR improvements than either modality alone.
Dietary composition: Reducing refined carbohydrates and fructose, increasing dietary fiber, and adequate protein intake all influence insulin sensitivity through different pathways. Low-carbohydrate diets consistently improve fasting insulin in short-term trials. Mediterranean-pattern diets show benefits in longer-term outcomes.
Sleep: Even a single night of partial sleep deprivation reduces insulin sensitivity by 20–25% in controlled studies. Chronic sleep insufficiency is an underweighted contributor to insulin resistance.
Hormone optimization: When testosterone deficiency, thyroid dysfunction, or cortisol dysregulation is contributing to insulin resistance, addressing the hormonal root cause can produce metabolic improvements that lifestyle alone does not fully achieve. See the TelosRX slow metabolism guide for context on hormonal contributions to metabolic rate.
What Do Fasting Insulin Levels Actually Mean?
Fasting insulin is one of the most underutilized metabolic markers in standard care. Standard reference ranges list up to 24.9 μIU/mL as “normal” — a threshold set to identify overt hyperinsulinemia, not optimal metabolic function.
Functional medicine and metabolic-focused providers generally target fasting insulin below 8–10 μIU/mL for individuals with metabolic optimization goals. A fasting insulin of 18 μIU/mL with a normal fasting glucose tells a very different clinical story than a fasting insulin of 5 μIU/mL with the same glucose — and standard lab flagging misses that difference entirely.
When interpreting fasting insulin, always pair it with fasting glucose to calculate HOMA-IR, and evaluate it alongside HbA1c and lipid values for a complete metabolic picture.
How Does Insulin Resistance Relate to Weight Gain?
The relationship between insulin resistance and weight is bidirectional. Excess visceral fat — particularly fat surrounding abdominal organs — secretes inflammatory cytokines (TNF-α, IL-6) and free fatty acids that impair insulin receptor signaling in liver and muscle. This creates insulin resistance. The elevated insulin that results then promotes further fat storage, particularly in visceral depots, completing the cycle.
This is why calorie restriction alone often yields disappointing long-term results in people with significant insulin resistance: the hormonal environment actively works against fat mobilization. Interventions that directly address insulin sensitivity — exercise, sleep, carbohydrate reduction, and where indicated, hormonal support — can shift the metabolic environment in a way that makes fat loss more tractable.
When Should Someone Consider Medical Evaluation for Insulin Resistance?
Evaluation is appropriate when any of the following apply:
- Fasting glucose between 100–125 mg/dL (prediabetes range)
- HbA1c between 5.7–6.4%
- HOMA-IR above 2.0 on prior lab work
- Central obesity (waist circumference above clinical thresholds) combined with fatigue and lipid abnormalities
- PCOS diagnosis in women
- Family history of type 2 diabetes combined with progressive weight gain
- Symptoms that worsen after carbohydrate intake despite otherwise reasonable diet quality
TelosRX providers evaluate insulin resistance in the context of a full hormone and metabolic panel. Patients complete an asynchronous intake — no video call or in-person appointment required — and receive a written clinical assessment. If intervention is appropriate, compounded or pharmaceutical treatment options are discussed in the provider’s written evaluation. Access is subject to medical approval. Start your evaluation at TelosRX.
What Is the Difference Between Insulin Resistance and Metabolic Syndrome?
Metabolic syndrome is a clinical diagnosis requiring three or more of the following five criteria (per ATP III / AHA/NHLBI guidelines):
- Waist circumference above 35 in (women) or 40 in (men)
- Fasting triglycerides ≥150 mg/dL
- HDL cholesterol below 50 mg/dL (women) or 40 mg/dL (men)
- Blood pressure ≥130/85 mmHg
- Fasting glucose ≥100 mg/dL
Insulin resistance is the underlying pathophysiology that drives most of those criteria. You can have clinically significant insulin resistance without meeting the full metabolic syndrome definition — particularly early in the process when only HOMA-IR and fasting insulin are elevated while other markers remain within range. Metabolic syndrome is essentially the late-stage, multi-system expression of years of uncorrected insulin resistance. See the TelosRX hormone optimization guide for discussion of how hormonal optimization intersects with metabolic syndrome markers in men undergoing TRT evaluation.
Frequently Asked Questions
Can you have insulin resistance with normal blood sugar?
Yes. Fasting glucose can remain normal for years while insulin resistance is present and progressing. The pancreas compensates by producing more insulin. Fasting glucose only rises — crossing into prediabetes territory — once beta-cell compensation begins to fail. Testing fasting insulin directly, rather than relying solely on glucose or HbA1c, catches this earlier.
Is insulin resistance genetic?
Genetic factors influence individual susceptibility — family history of type 2 diabetes is a meaningful risk factor. However, insulin resistance is strongly modifiable through lifestyle and, where appropriate, medical intervention. Genetics establishes a threshold, not a destiny.
Does intermittent fasting help insulin resistance?
Short-term trial data shows that intermittent fasting protocols reduce fasting insulin and HOMA-IR in people with obesity or prediabetes. Effects are largely mediated by caloric reduction and the period of low insulin during the fasting window. It is a viable intervention for appropriate candidates, not a universal recommendation.
What medications are used for insulin resistance?
Metformin is the most prescribed insulin sensitizer. GLP-1 receptor agonists (semaglutide, tirzepatide) reduce insulin resistance through multiple mechanisms including weight reduction. Both are FDA-approved pharmaceuticals. Compounded GLP-1 formulations are also available through licensed telehealth pharmacies and require provider evaluation and approval.
Can low testosterone cause insulin resistance in men?
Yes — the association is well-documented. Low testosterone reduces muscle mass and promotes visceral fat accumulation, both of which worsen insulin sensitivity. Testosterone replacement in hypogonadal men with metabolic dysfunction has shown improvements in insulin sensitivity in controlled trials, alongside expected body composition changes.
How quickly can insulin resistance improve with intervention?
Studies show measurable improvements in HOMA-IR within 4–12 weeks of consistent aerobic exercise or dietary carbohydrate restriction. The timeline depends on intervention intensity, baseline severity, and whether contributing hormonal factors are addressed. Individual results vary and cannot be predicted in advance.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.